Galera Reports First Quarter 2023 Financial Results and Recent Corporate Updates
11 mai 2023 07h00 HE
|
Galera Therapeutics
Avasopasem NDA granted FDA priority review for radiotherapy-induced severe oral mucositis (SOM); PDUFA target date of August 9, 2023 Company raised $30 million in gross proceeds from registered...
Galera Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 mai 2023 16h01 HE
|
Galera Therapeutics
MALVERN, Pa., May 04, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Expands Commercial Leadership Team
01 mai 2023 07h00 HE
|
Galera Therapeutics
Company appoints leading sales, market access and operations executives with decades of experience successfully launching and commercializing new oncology products New Drug Application (NDA) for...
Galera to Present One-Year Reductions in Cisplatin-Related Chronic Kidney Disease Data from ROMAN Trial at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
26 avr. 2023 10h00 HE
|
Galera Therapeutics
MALVERN, Pa., April 26, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck Oncology
10 mars 2023 07h00 HE
|
Galera Therapeutics
MALVERN, Pa., March 10, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates
08 mars 2023 07h00 HE
|
Galera Therapeutics
Avasopasem NDA granted FDA priority review for radiotherapy-induced severe oral mucositis (SOM); PDUFA target date of August 9, 2023 Company raised $30 million in gross proceeds from registered...
Galera Therapeutics Announces Pricing of Registered Direct Offering of $30 Million of Common Stock and Warrants
15 févr. 2023 08h45 HE
|
Galera Therapeutics
MALVERN, Pa., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Announces FDA Acceptance and Priority Review of Avasopasem NDA for Radiotherapy-Induced Severe Oral Mucositis
15 févr. 2023 08h00 HE
|
Galera Therapeutics
PDUFA target date of August 9, 2023 Avasopasem would be first drug approved for SOM in patients with head and neck cancer MALVERN, Pa., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics,...
Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis
12 déc. 2022 07h00 HE
|
Galera Therapeutics
MALVERN, Pa., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera to Present at Piper Sandler Annual Healthcare Conference
22 nov. 2022 07h00 HE
|
Galera Therapeutics
MALVERN, Pa., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...